Shots:

• ViiV Healthcare has renewed its research agreement with UNC-Chapel Hill to the tune of ~$20M over five years for solely focus on the discovery of therapies for HIV
• The scientists from both the companies will work at the HIV Cure Center- which was created in 2015 at the start of the collaboration. The public-private collaboration will continue to jointly own Qura Therapeutics- a company managing the IP- commercialization- manufacturing and governance needs of the alliance
• The partnership is the first-of-its-kind in HIV that brings academic and pharmaceutical research scientists together for developing a new approach to eradicate HIV

Click here ­to­ read full press release/ article | Ref: GSK | Image: Pinterest